Interleukin-2 (IL-2), a protein produced primarily by CD4+ T-cells that activates and induces proliferation of natural killer (NK) cells, CD8+, and CD4+ T cells, is FDA-approved for the treatment of metastatic melanoma. This evidence concerns the gene CD8A and metastatic melanoma.